Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma.

IF 4.4 2区医学 Q1 ONCOLOGY Cancers Pub Date : 2023-01-24 DOI:10.3390/cancers15030719

Shun Ishido, Kaoru Tsuchiya, Yoshihito Kano, Yutaka Yasui, Kenta Takaura, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Hiroaki Matsumoto, Tsubasa Nobusawa, Taisei Keitoku, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Yuka Takahashi, Hiroyuki Nakanishi, Urara Sakurai, Yasuhiro Asahina, Ryuichi Okamoto, Masayuki Kurosaki, Namiki Izumi

{"title":"Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma.","authors":"Shun Ishido, Kaoru Tsuchiya, Yoshihito Kano, Yutaka Yasui, Kenta Takaura, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Hiroaki Matsumoto, Tsubasa Nobusawa, Taisei Keitoku, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Yuka Takahashi, Hiroyuki Nakanishi, Urara Sakurai, Yasuhiro Asahina, Ryuichi Okamoto, Masayuki Kurosaki, Namiki Izumi","doi":"10.3390/cancers15030719","DOIUrl":null,"url":null,"abstract":"The molecular mechanism of hepatocellular carcinoma (HCC) is partially demonstrated. Moreover, in the patients receiving multiple molecular-targeted therapies, the gene alternations are still unknown. Six molecular-targeted therapies of unresectable HCC (uHCC) and comprehensive genomic profiling (CGP) have been approved in clinical practice. Hence, the utility of CGP in patients with uHCC treated with multiple molecular-targeted agents is investigated. The data of the patients with uHCC who received CGP tests were collected, retrospectively, between February 2021 and May 2022. Gene alterations detected by foundation testing, excluding variants of unknown significance, were reported in all nine patients. The samples for CGP were derived from liver tumor biopsy (n = 2), surgical specimens of bone metastases (n = 2), and blood (n = 5). The median number of systemic therapies was four. Seven patients were candidates eligible for clinical trials. One patient with a high tumor mutation burden (TMB) could receive pembrolizumab after CGP. This study presented genomic alternations after receiving multiple molecular-targeted therapies. However, further investigation needs to be conducted to develop personalized therapies and invent newer agents for treating HCC.","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"15 3","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2023-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913078/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers15030719","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

The molecular mechanism of hepatocellular carcinoma (HCC) is partially demonstrated. Moreover, in the patients receiving multiple molecular-targeted therapies, the gene alternations are still unknown. Six molecular-targeted therapies of unresectable HCC (uHCC) and comprehensive genomic profiling (CGP) have been approved in clinical practice. Hence, the utility of CGP in patients with uHCC treated with multiple molecular-targeted agents is investigated. The data of the patients with uHCC who received CGP tests were collected, retrospectively, between February 2021 and May 2022. Gene alterations detected by foundation testing, excluding variants of unknown significance, were reported in all nine patients. The samples for CGP were derived from liver tumor biopsy (n = 2), surgical specimens of bone metastases (n = 2), and blood (n = 5). The median number of systemic therapies was four. Seven patients were candidates eligible for clinical trials. One patient with a high tumor mutation burden (TMB) could receive pembrolizumab after CGP. This study presented genomic alternations after receiving multiple molecular-targeted therapies. However, further investigation needs to be conducted to develop personalized therapies and invent newer agents for treating HCC.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

综合基因组图谱在不可切除肝细胞癌患者中的临床应用。

肝细胞癌(HCC)的分子机制部分得到证实。此外，在接受多种分子靶向治疗的患者中，基因改变仍然是未知的。六种分子靶向治疗不可切除HCC (uHCC)和综合基因组分析(CGP)已被批准用于临床实践。因此，CGP在接受多分子靶向药物治疗的uHCC患者中的应用被研究。回顾性收集2021年2月至2022年5月期间接受CGP检查的uHCC患者的数据。通过基础检测检测到的基因改变(不包括未知意义的变异)在所有9例患者中均有报道。CGP的样本来自肝脏肿瘤活检(n = 2)、骨转移手术标本(n = 2)和血液(n = 5)。全身治疗的中位数为4次。7例患者有资格参加临床试验。1例高肿瘤突变负荷(TMB)患者可在CGP后接受派姆单抗治疗。本研究展示了接受多种分子靶向治疗后的基因组变化。然而，需要进一步的研究来开发个性化的治疗方法和发明治疗HCC的新药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancers Medicine-Oncology

CiteScore

8.00

自引率

9.60%

发文量

5371

审稿时长

18.07 days

期刊介绍： Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.